Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + SOC in First-Line Metastatic Colorectal Cancer
NCT03414983Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of nivolumab in metastatic colorectal cancer (mCRC), sponsored by Bristol Myers Squibb. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03414983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414983.